{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:33:35Z","timestamp":1790854415769,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2222,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1002\/hep.22991","type":"journal-article","created":{"date-parts":[[2009,4,6]],"date-time":"2009-04-06T17:46:06Z","timestamp":1239039966000},"page":"369-377","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":43,"title":["Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1\u2013infected patients\u2020\u2021"],"prefix":"10.1097","volume":"50","author":[{"given":"Thomas","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Weich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlinde","family":"Teuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Rasenack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Hinrichsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Gerlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Spengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buggisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Balk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrga","family":"Zankel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20241201","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(97)07361-3","article-title":"Hepatitis C","volume":"351","author":"Di Bisceglie","year":"1998","journal-title":"Lancet"},{"key":"R2-8-20241201","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJM200107053450107","article-title":"Hepatitis C virus infection","volume":"345","author":"Lauer","year":"2001","journal-title":"N Eng J Med"},{"key":"R3-8-20241201","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1002\/hep.510260711","article-title":"Epidemiology of hepatitis C","volume":"26","author":"Alter","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R4-8-20241201","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","article-title":"Global epidemiology of hepatitis C virus infection","volume":"5","author":"Shepard","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"R5-8-20241201","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4088\/JCP.v66n0106","article-title":"Depression during pegylated interferon\u2010alpha plus ribavirin therapy: prevalence and prediction","volume":"66","author":"Raison","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R6-8-20241201","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMct061675","article-title":"Peginterferon and ribavirin for chronic hepatitis C","volume":"355","author":"Hoofnagle","year":"2006","journal-title":"N Engl J Med"},{"key":"R7-8-20241201","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon\u2010alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"R8-8-20241201","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2893.2006.00817.x","article-title":"Short\u2010duration therapy for hepatitis C: suitable for all?","volume":"14","author":"Mangia","year":"2007","journal-title":"J Viral Hepat"},{"key":"R9-8-20241201","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1053\/j.gastro.2005.05.008","article-title":"Peginterferon\u2010alpha\u20102a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C","volume":"129","author":"von Wagner","year":"2005","journal-title":"Gastroenterology"},{"key":"R10-8-20241201","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jhep.2005.10.003","article-title":"Efficacy of 24 weeks treatment with peginterferon alfa\u20102b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia","volume":"44","author":"Zeuzem","year":"2006","journal-title":"J Hepatol"},{"key":"R11-8-20241201","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","article-title":"Classification of chronic hepatitis: diagnosis, grading and staging","volume":"19","author":"Desmet","year":"1994","journal-title":"HEPATOLOGY"},{"key":"R12-8-20241201","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1086\/382279","article-title":"A 48\u2010week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long\u2010term response among patients infected with genotype\u20101 hepatitis C virus","volume":"189","author":"Drusano","year":"2004","journal-title":"J Infect Dis"},{"key":"R14-8-20241201","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2893.2007.00921.x","article-title":"Antiviral therapy: chronic hepatitis C","volume":"14","author":"Heathcote","year":"2007","journal-title":"J Viral Hepat"},{"key":"R15-8-20241201","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.21159","article-title":"Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha\u20102a (40 kd)\/ribavirin therapy","volume":"43","author":"Jensen","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R16-8-20241201","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2008.04.015","article-title":"Peginterferon alfa\u20102a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response","volume":"135","author":"Ferenci","year":"2008","journal-title":"Gastroenterology"},{"key":"R17-8-20241201","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.22319","article-title":"Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial","volume":"47","author":"Yu","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R18-8-20241201","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/hep.21265","article-title":"HCV RNA detection by TMA during the hepatitis C antiviral long\u2010term treatment against cirrhosis (Halt\u2010C) trial","volume":"44","author":"Morishima","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R19-8-20241201","first-page":"317A","article-title":"Importance of a minimal residual viremia for the relapse prediction in HCV type 1 patients receiving standard or individualized treatment duration","volume":"46","author":"Berg","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R20-8-20241201","first-page":"360A","article-title":"Time to HCV RNA negativation in hepatitis C virus (HCV) type 1\u2010infection during PEG\u2010interferon alpha\u20102B plus ribavirin therapy: differences in relation to the assay sensitivity (Indiv\u20101 study group)","volume":"46","author":"Berg","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R21-8-20241201","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/135965350801301S03","article-title":"Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4","volume":"13","author":"Lee","year":"2008","journal-title":"Antivir Ther"},{"key":"R22-8-20241201","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/135965350801301S01","article-title":"Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3","volume":"13","author":"Berg","year":"2008","journal-title":"Antivir Ther"},{"issue":"Suppl","key":"R23-8-20241201","first-page":"267A","article-title":"Improving the clinical relevance of pretreatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa 2a (40 KD) (Pegasys) plus ribavirin (Copegus) Abstract 2009.","volume":"44","author":"Zeuzem","year":"2006","journal-title":""},{"key":"R24-8-20241201","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1053\/j.gastro.2006.02.015","article-title":"Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon\u2010alfa\u20102a plus ribavirin","volume":"130","author":"Berg","year":"2006","journal-title":"Gastroenterology"},{"key":"R25-8-20241201","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2006.05.016","article-title":"Peginterferon\u2010alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment","volume":"131","author":"Sanchez\u2010Tapias","year":"2006","journal-title":"Gastroenterology"},{"key":"R26-8-20241201","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1002\/hep.21919","article-title":"Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1\u2010infected slow responders","volume":"46","author":"Pearlman","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R27-8-20241201","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.22061","article-title":"Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial","volume":"47","author":"Mangia","year":"2008","journal-title":"HEPATOLOGY"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22991","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200908000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:26:56Z","timestamp":1733059616000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200908000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22991","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}